Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Sangamo Therapeutics, Inc. SGMO
$1.32
+$0.02 (1.54%)
На 18:00, 12 мая 2023
+809.09%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
227200400.00000000
-
week52high
6.42
-
week52low
1.18
-
Revenue
111299000
-
P/E TTM
-1
-
Beta
1.06920400
-
EPS
-1.13000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 10:59
Описание компании
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Truist Securities | Buy | Buy | 05 апр 2022 г. |
| RBC Capital | Outperform | 04 мая 2021 г. | |
| Stifel | Hold | 06 янв 2021 г. | |
| B of A Securities | Buy | Buy | 08 сент 2020 г. |
| SunTrust Robinson Humphrey | Buy | 07 июл 2020 г. | |
| Wells Fargo | Overweight | Overweight | 07 ноя 2022 г. |
| Wells Fargo | Overweight | Overweight | 04 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Beers Courtney | A | 37500 | 37500 | 15 дек 2022 г. |
| Beers Courtney | A | 18750 | 18750 | 15 дек 2022 г. |
| Horn Margaret A | A | 37500 | 37500 | 15 дек 2022 г. |
| Horn Margaret A | A | 18750 | 18750 | 15 дек 2022 г. |
| BIOGEN INC. | D | 23652466 | 100000 | 30 авг 2022 г. |
| BIOGEN INC. | D | 23752466 | 400000 | 29 авг 2022 г. |
| Willoughby Scott B. | D | 92966 | 864 | 13 авг 2022 г. |
| McClung David Mark | D | 175816 | 11525 | 25 июн 2022 г. |
| Duraibabu Prathyusha | D | 86617 | 842 | 11 июн 2022 г. |
| Markels John | A | 32484 | 6784 | 03 июн 2022 г. |
Новостная лента
7 Sorry Pharma Stocks to Sell in April Before It's Too Late
InvestorPlace
16 апр 2023 г. в 06:30
Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing in pharma stocks can also mean heavy expenditures on research and testing for a drug that may not perform as well as scientists hope.
Sangamo: Hemophilia A Program With Pfizer Key To Success
Seeking Alpha
23 мар 2023 г. в 02:52
Final results from the phase 3 AFFINE trial using giroctocogene fitelparvovec for the treatment of patients with Hemophilia A are expected in the 1st half of 2024. If phase 3 trial is successful, Pfizer will be able to file BLA to the FDA of giroctocogene fitelparvovec for the treatment of patients with Hemophilia A 2nd half 2024.
7 CRISPR Stocks With the Best Long-Term Potential
InvestorPlace
30 янв 2023 г. в 19:10
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis.
3 Undervalued Penny Stocks According To Analysts
PennyStocks
16 дек 2022 г. в 14:17
Penny stocks to buy according to analysts. Are they right?
Sangamo Therapeutics: Ready To Dust Off My Dormant Position Ahead Of A Pivotal 2023
Seeking Alpha
19 ноя 2022 г. в 21:47
Sangamo Therapeutics is developing groundbreaking genomic and cell therapies for the treatment of some of the worst diseases known to man. I review the company's recent progress and will provide my views on the company's current condition.